Drug profile · INN
midazolam hydrochloride
MIDAZOLAM HYDROCHLORIDE
midazolam hydrochloride (MIDAZOLAM HYDROCHLORIDE) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: intramuscular. Current US regulatory status: approved.
Drug details — midazolam hydrochloride
- US status
- approved
- Class
- —
- Route
- INTRAMUSCULAR
- Patents
- 2
- Programs
- 1
- Data quality
- 0.84
Quick answer
midazolam hydrochloride (MIDAZOLAM HYDROCHLORIDE) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: intramuscular. Current US regulatory status: approved.
Key facts
Mechanism of action
GABA-A receptor; anion channel positive allosteric modulator
Primary target: GABA-A receptor; anion channel
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is midazolam hydrochloride?
midazolam hydrochloride (MIDAZOLAM HYDROCHLORIDE) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: intramuscular. Current US regulatory status: approved.
What is the brand name for midazolam hydrochloride?
MIDAZOLAM HYDROCHLORIDE is a marketed brand name for midazolam hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of midazolam hydrochloride?
midazolam hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.